TMIGD3

Summary

TMIGD3 (transmembrane and immunoglobulin domain containing 3, HGNC:51375) is a protein-coding gene on chromosome 1p13.2, encoding Transmembrane domain-containing protein TMIGD3 (P0DMS9). Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity.

This gene encodes a transmembrane and immunoglobulin domain-containing protein. Alternative splicing results in multiple transcript variants, one of which shares its 5’ terminal exon with that of the overlapping adenosine A3 receptor gene (GeneID:140), thus resulting in a fusion product.

Source: NCBI Gene 57413 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 3 total
• Phenotypes (HPO): 1
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_020683

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:51375
Approved symbol	TMIGD3
Name	transmembrane and immunoglobulin domain containing 3
Location	1p13.2
Locus type	gene with protein product
Status	Approved
Aliases	AD026
Ensembl gene	ENSG00000121933
Ensembl biotype	protein_coding
OMIM	621207
Entrez	57413

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 4 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000369716, ENST00000369717, ENST00000442484, ENST00000443498, ENST00000463993, ENST00000472933

RefSeq mRNA: 3 — MANE Select: NM_020683 NM_001081976, NM_001302680, NM_020683

CCDS: CCDS41369, CCDS838

Canonical transcript exons

ENST00000369716 — 6 exons

Exon	Start	End
ENSE00001068684	111490656	111490762
ENSE00001644858	111483348	111483757
ENSE00001804797	111485740	111485840
ENSE00001848893	111503005	111503633
ENSE00003463676	111486586	111486652
ENSE00003562338	111488677	111489024

Expression profiles

Bgee: expression breadth ubiquitous, 178 present calls, max score 93.11.

FANTOM5 (CAGE): breadth broad, TPM avg 2.5990 / max 743.2736, expressed in 199 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
13821	1.8645	149
13829	0.7224	186
13825	0.2970	93
13827	0.1371	58
13823	0.0772	36
13822	0.0722	24
13838	0.0676	3
13824	0.0556	23
13837	0.0180	3
13826	0.0099	4

Top tissues by expression

251 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	93.11	gold quality
right testis	UBERON:0004534	91.98	gold quality
testis	UBERON:0000473	91.01	gold quality
sperm	CL:0000019	89.09	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	88.29	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	85.61	gold quality
adult organism	UBERON:0007023	85.45	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.92	gold quality
spinal cord	UBERON:0002240	84.27	gold quality
right adrenal gland cortex	UBERON:0035827	84.23	gold quality
right adrenal gland	UBERON:0001233	83.71	gold quality
left adrenal gland	UBERON:0001234	83.71	gold quality
substantia nigra	UBERON:0002038	83.60	gold quality
left adrenal gland cortex	UBERON:0035825	83.07	gold quality
midbrain	UBERON:0001891	82.64	gold quality
inferior vagus X ganglion	UBERON:0005363	82.36	gold quality
adrenal cortex	UBERON:0001235	81.44	gold quality
medial globus pallidus	UBERON:0002477	81.42	gold quality
adrenal gland	UBERON:0002369	80.48	gold quality
corpus callosum	UBERON:0002336	80.29	gold quality
amniotic fluid	UBERON:0000173	80.13	gold quality
amygdala	UBERON:0001876	79.90	gold quality
Brodmann (1909) area 46	UBERON:0006483	78.59	gold quality
prefrontal cortex	UBERON:0000451	78.49	gold quality
hypothalamus	UBERON:0001898	78.15	gold quality
spleen	UBERON:0002106	78.15	gold quality
putamen	UBERON:0001874	78.04	gold quality
Brodmann (1909) area 9	UBERON:0013540	77.88	gold quality
placenta	UBERON:0001987	77.41	gold quality
Ammon’s horn	UBERON:0001954	76.30	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-9435	yes	922.67
E-MTAB-6701	yes	44.95
E-ANND-3	yes	6.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

19 targeting TMIGD3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-593-3P	99.22	67.28	1327
HSA-MIR-6755-3P	98.61	66.90	834
HSA-MIR-7158-3P	98.46	66.45	728
HSA-MIR-6837-3P	98.42	66.71	1149
HSA-MIR-4511	98.32	67.97	1500
HSA-MIR-3921	97.81	67.45	1431
HSA-MIR-7112-3P	97.67	68.77	948
HSA-MIR-6069	97.45	65.88	357
HSA-MIR-4640-5P	97.42	66.33	1543
HSA-MIR-526B-5P	97.41	67.99	1074
HSA-MIR-4726-5P	97.24	65.67	1299
HSA-MIR-4653-5P	97.22	67.72	1429
HSA-MIR-3156-5P	96.93	67.36	800
HSA-MIR-383-5P	96.86	67.55	820
HSA-MIR-345-5P	96.40	66.43	663

Literature-anchored findings (GeneRIF, showing 1)

• Protein expression of TMIGD3 and A3AR is lower in human osteosarcoma tissues than normal tissues. Mechanistically, TMIGD3 isoform 1 and A3AR commonly inhibit the PKA-Akt-NF-kappaB axis. (PMID:27886186)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Tmigd3	ENSMUSG00000074344
rattus_norvegicus	Tmigd3	ENSRNOG00000043375

Paralogs (13): TREM2 (ENSG00000095970), CD300LG (ENSG00000161649), TREML1 (ENSG00000161911), FCMR (ENSG00000162894), PIGR (ENSG00000162896), FCAMR (ENSG00000162897), CD300C (ENSG00000167850), CD300A (ENSG00000167851), CD300LB (ENSG00000178789), CD300LF (ENSG00000186074), CD300E (ENSG00000186407), CD300LD (ENSG00000204345), CD300H (ENSG00000284690)

Protein

Protein identifiers

Transmembrane domain-containing protein TMIGD3 — P0DMS9 (reviewed: P0DMS9)

All UniProt accessions (3): A0A0J9YY46, P0DMS9, Q5QNY8

UniProt curated annotations — full annotation on UniProt →

Function. Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity.

Subcellular location. Membrane.

Tissue specificity. Expressed in the lung and bone. Expressed at lower levels in osteosarcoma tissues (at protein level).

Miscellaneous. The first exon of TMIGD3 isoform 1 (i1) is shared with the first exon of ADORA3 isoform 2 (A3AR i2, commonly known as A3AR), resulting in a fusion protein.

Isoforms (3)

UniProt ID	Names	Canonical?
P0DMS9-1	3, TMIGD3 i3, A3AR i3	yes
P0DMS9-2	1, TMIGD3 i1, A3AR i1
P0DMS8-1	2, A3AR i2, A3AR

RefSeq proteins (3): NP_001075445, NP_001289609, NP_065734* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR050671	CD300_family_receptors	Family

UniProt features (6 total): transmembrane region 2, chain 1, region of interest 1, glycosylation site 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P0DMS9-F1	70.83	0.35

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (1): 192

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 65 (showing top): GOBP_CIRCULATORY_SYSTEM_PROCESS, GOBP_INFLAMMATORY_RESPONSE, GOBP_POSITIVE_REGULATION_OF_LYASE_ACTIVITY, GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY, GOBP_REGULATION_OF_ADENYLATE_CYCLASE_ACTIVITY, GOBP_REGULATION_OF_IMMUNE_RESPONSE, GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION, GOBP_NEGATIVE_REGULATION_OF_NF_KAPPAB_TRANSCRIPTION_FACTOR_ACTIVITY, GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION, GOBP_REGULATION_OF_SYSTEM_PROCESS, GOBP_HEART_PROCESS, TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_DN, GOBP_REGULATION_OF_BLOOD_CIRCULATION, GOBP_REGULATION_OF_DNA_BINDING_TRANSCRIPTION_FACTOR_ACTIVITY, KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP

GO Biological Process (10): immune response-activating signaling pathway (GO:0002757), inflammatory response (GO:0006954), signal transduction (GO:0007165), activation of adenylate cyclase activity (GO:0007190), regulation of heart contraction (GO:0008016), negative regulation of cell population proliferation (GO:0008285), response to wounding (GO:0009611), negative regulation of cell migration (GO:0030336), obsolete negative regulation of NF-kappaB transcription factor activity (GO:0032088), G protein-coupled receptor signaling pathway (GO:0007186)

GO Molecular Function (2): transmembrane signaling receptor activity (GO:0004888), G protein-coupled receptor activity (GO:0004930)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
activation of immune response	1
immune response-regulating signaling pathway	1
defense response	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
positive regulation of adenylate cyclase activity	1
heart contraction	1
regulation of blood circulation	1
cell population proliferation	1
regulation of cell population proliferation	1
negative regulation of cellular process	1
response to stress	1
cell migration	1
regulation of cell migration	1
negative regulation of cell motility	1
G protein-coupled receptor activity	1
signal transduction	1
signaling receptor activity	1
transmembrane signaling receptor activity	1
G protein-coupled receptor signaling pathway	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

452 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TMIGD3	TMIGD1	Q6UXZ0	583
TMIGD3	FAM124A	Q86V42	470
TMIGD3	EVI2A	P22794	396
TMIGD3	PDLIM3	Q53GG5	375
TMIGD3	SPATC1	Q76KD6	366
TMIGD3	TMIGD2	Q96BF3	358
TMIGD3	APH1B	Q8WW43	353
TMIGD3	SNX31	Q8N9S9	353
TMIGD3	MT-ND3	P03897	353
TMIGD3	ABCA1	O95477	353
TMIGD3	FGA	P02671	353
TMIGD3	IL24	Q13007	353
TMIGD3	CCL15	Q16663	353
TMIGD3	MAP3K14	Q99558	353
TMIGD3	CENPV	Q7Z7K6	350

IntAct

0 interactions, top by confidence:

ESM2 similar proteins: A2A7V7, A2TGX5, A5D7B2, G3X8R9, O88875, O95944, P0DMS9, P11912, P12318, P15530, P16410, P22273, P31785, P31994, P31995, P34902, P40259, P50283, Q02242, Q1ERP8, Q2LA85, Q2YFS1, Q2YFS2, Q2YFS3, Q3LRV9, Q3U497, Q566E6, Q5T2D2, Q60513, Q6SJQ0, Q6SJQ5, Q6SJQ7, Q6TYI6, Q6UXG3, Q6UXN2, Q7TSN2, Q86YW5, Q8K558, Q8SPV8, Q8TDQ1

Diamond homologs: A0A0K2S4Q6, A2A7V7, A2TGX5, A5D7B2, A8K4G0, G3X8R9, O95944, P01832, P01833, P0DMS9, P0DUB1, P15083, P81265, Q08708, Q1ERP8, Q2LA85, Q3U497, Q496F6, Q566E6, Q6SJQ0, Q6SJQ5, Q6SJQ7, Q6UXG3, Q6UXZ3, Q7TSN2, Q8K249, Q8TDQ1, Q8VCH2, Q9UGN4, O70570, A1KXC4, O60667, Q29244, Q2TB54, Q3LRV9, Q5M871, Q5R770, Q6UXN2, Q8WWV6, Q64JA4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

3 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	2
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1010 predictions. Top by Δscore:

Variant	Effect	Δscore
1:111486581:CTCA:C	donor_loss	1.0000
1:111486582:TCAC:T	donor_loss	1.0000
1:111486583:CA:C	donor_loss	1.0000
1:111486584:ACCTG:A	donor_loss	1.0000
1:111486585:C:CT	donor_loss	1.0000
1:111486653:C:CC	acceptor_gain	1.0000
1:111488672:CTTA:C	donor_loss	1.0000
1:111488673:TTACC:T	donor_loss	1.0000
1:111488674:TACC:T	donor_loss	1.0000
1:111488675:A:AC	donor_gain	1.0000
1:111488676:C:A	donor_loss	1.0000
1:111488676:C:CC	donor_gain	1.0000
1:111488676:CCTTT:C	donor_gain	1.0000
1:111542312:G:GT	donor_gain	1.0000
1:111542389:G:GT	donor_gain	1.0000
1:111485738:A:AC	donor_gain	0.9900
1:111485738:AC:A	donor_gain	0.9900
1:111485738:ACC:A	donor_gain	0.9900
1:111485738:ACCC:A	donor_gain	0.9900
1:111485739:C:CC	donor_gain	0.9900
1:111485739:CC:C	donor_gain	0.9900
1:111485739:CCC:C	donor_gain	0.9900
1:111485739:CCCC:C	donor_gain	0.9900
1:111485837:CGTC:C	acceptor_gain	0.9900
1:111486584:A:AC	donor_gain	0.9900
1:111486585:C:CC	donor_gain	0.9900
1:111486648:TAGGT:T	acceptor_gain	0.9900
1:111486649:AGGT:A	acceptor_gain	0.9900
1:111486650:GGT:G	acceptor_gain	0.9900
1:111486651:GT:G	acceptor_gain	0.9900

AlphaMissense

2285 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:111503182:T:A	D58V	0.999
1:111503182:T:G	D58A	0.999
1:111503183:C:G	D58H	0.999
1:111503032:C:G	R108P	0.998
1:111503181:G:C	D58E	0.998
1:111503181:G:T	D58E	0.998
1:111503182:T:C	D58G	0.998
1:111503265:G:C	N30K	0.998
1:111503265:G:T	N30K	0.998
1:111503171:C:G	G62R	0.996
1:111503171:C:T	G62R	0.996
1:111503194:A:G	L54P	0.996
1:111503270:C:G	G29R	0.996
1:111503171:C:A	G62W	0.995
1:111503183:C:A	D58Y	0.995
1:111503053:A:C	L101W	0.994
1:111503041:G:T	A105D	0.993
1:111503042:C:G	A105P	0.993
1:111503053:A:G	L101S	0.993
1:111503065:G:T	S97Y	0.993
1:111503106:G:C	C83W	0.993
1:111503170:C:T	G62E	0.993
1:111503191:G:T	A55D	0.993
1:111503288:C:G	G23R	0.993
1:111503288:C:T	G23R	0.993
1:111503194:A:T	L54Q	0.992
1:111503065:G:A	S97F	0.991
1:111503108:A:G	C83R	0.991
1:111503192:C:G	A55P	0.991
1:111503269:C:T	G29D	0.991

dbSNP variants (sampled 300 via entrez): RS1000035687 (1:111511080 T>G), RS1000038056 (1:111544076 T>G), RS1000088595 (1:111543861 T>G), RS1000089426 (1:111484580 T>C,G), RS1000159733 (1:111490581 G>A), RS1000177935 (1:111501179 G>A,T), RS1000189873 (1:111531488 A>G), RS1000224683 (1:111502481 AAT>A,AATAT), RS1000254176 (1:111549412 G>A), RS1000348153 (1:111551008 G>A), RS1000357017 (1:111485389 C>T), RS1000427514 (1:111536577 T>C), RS1000474881 (1:111531718 T>C), RS1000528795 (1:111532834 C>T), RS1000544344 (1:111502806 T>C)

Disease associations

OMIM: gene MIM:621207 | disease phenotypes: MIM:209850

GenCC curated gene-disease

Mondo (1): autism (MONDO:0005260)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000717	Autism

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3712907 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 752 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1355736	THEOPHYLLINE	4	752

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

5 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs3394	ADORA3, TMIGD3		0.00	0
rs2298191	ADORA3, TMIGD3		0.00	0
rs3393	ADORA3, TMIGD3		0.00	0
rs35511654	ADORA3, TMIGD3		0.00	0
rs1544223	ADORA3, TMIGD3		0.00	0

ChEMBL bioactivities

151 potent at pChembl≥5 of 161 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.27	Ki	0.54	nM	CHEMBL3747303
9.24	Ki	0.58	nM	CHEMBL3746778
9.16	Ki	0.69	nM	CHEMBL3746260
9.14	Ki	0.73	nM	CHEMBL3612943
9.07	Ki	0.85	nM	CHEMBL3747005
9.07	Ki	0.85	nM	CHEMBL3747209
9.04	Ki	0.91	nM	CHEMBL3746512
9.02	Ki	0.96	nM	CHEMBL3746358
9.02	Ki	0.95	nM	CHEMBL3746774
9.02	Ki	0.96	nM	CHEMBL3747276
8.97	Ki	1.06	nM	CHEMBL3747457
8.97	Ki	1.08	nM	CHEMBL3746487
8.91	Ki	1.22	nM	CHEMBL3612944
8.91	Ki	1.22	nM	CHEMBL3747461
8.90	Ki	1.25	nM	CHEMBL3745837
8.81	Ki	1.53	nM	CHEMBL3746890
8.81	Ki	1.55	nM	CHEMBL4090355
8.77	Ki	1.69	nM	CHEMBL3612940
8.73	Ki	1.84	nM	CHEMBL3747756
8.67	Ki	2.16	nM	CHEMBL3745807
8.66	Ki	2.21	nM	CHEMBL3747321
8.50	EC50	3.16	nM	CHEMBL3800048
8.46	Ki	3.48	nM	CHEMBL3747670
8.27	Ki	5.38	nM	CHEMBL4066973
8.24	Ki	5.78	nM	CHEMBL4105127
8.22	Ki	6.01	nM	CHEMBL3800048
8.20	Ki	6.25	nM	CHEMBL4086593
8.19	Ki	6.42	nM	CHEMBL4097426
8.18	Ki	6.66	nM	CHEMBL3746784
8.15	Ki	7.05	nM	CHEMBL3745851
8.14	Ki	7.31	nM	CHEMBL4089071
8.07	Ki	8.56	nM	CHEMBL4071830
8.04	Ki	9.02	nM	CHEMBL3746886
8.03	Ki	9.33	nM	CHEMBL4071867
7.94	Ki	11.5	nM	CHEMBL4092411
7.90	EC50	12.5	nM	CHEMBL3798200
7.84	Ki	14.5	nM	CHEMBL4093756
7.80	Ki	16	nM	NECA
7.76	Ki	17.5	nM	CHEMBL4068757
7.72	Ki	19	nM	CHEMBL111545
7.63	Ki	23.5	nM	CHEMBL3985712
7.61	Ki	24.4	nM	CHEMBL4081194
7.60	Ki	25	nM	CHEMBL4068878
7.57	EC50	26.9	nM	CHEMBL3799738
7.54	Ki	29	nM	CHEMBL3741217
7.50	Ki	31.4	nM	CHEMBL3771367
7.47	Ki	33.88	nM	CHEMBL3745868
7.47	Ki	34	nM	CHEMBL3976121
7.42	Ki	38	nM	CHEMBL4091060
7.40	Ki	40	nM	CHEMBL3745868

PubChem BioAssay actives

127 with measured affinity, of 308 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(1S,2R,3S,4R,5S)-4-[2-azido-6-(methylamino)purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1266313: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyl-uronamide from human adenosine A3 receptor stably expressed in CHO cell membrane by radioligand binding assay	ki	0.0005	uM
(1S,2R,3S,4R,5S)-4-[2-[4-(5-bromothiophen-2-yl)triazol-1-yl]-6-(methylamino)purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1266313: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyl-uronamide from human adenosine A3 receptor stably expressed in CHO cell membrane by radioligand binding assay	ki	0.0006	uM
(1S,2R,3S,4R,5S)-4-[2-[4-(5-chlorothiophen-2-yl)triazol-1-yl]-6-(methylamino)purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1266313: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyl-uronamide from human adenosine A3 receptor stably expressed in CHO cell membrane by radioligand binding assay	ki	0.0007	uM
(1S,2R,3S,4R,5S)-4-[2-azido-6-(ethylamino)purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1266313: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyl-uronamide from human adenosine A3 receptor stably expressed in CHO cell membrane by radioligand binding assay	ki	0.0007	uM
(1S,2R,3S,4R,5S)-4-[2-azido-6-(2-phenylethylamino)purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1266313: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyl-uronamide from human adenosine A3 receptor stably expressed in CHO cell membrane by radioligand binding assay	ki	0.0008	uM
(1S,2R,3S,4R,5S)-4-[2-azido-6-(cyclobutylamino)purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1266313: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyl-uronamide from human adenosine A3 receptor stably expressed in CHO cell membrane by radioligand binding assay	ki	0.0008	uM
(1S,2R,3S,4R,5S)-4-[2-[4-(2-chlorophenyl)triazol-1-yl]-6-(methylamino)purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1266313: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyl-uronamide from human adenosine A3 receptor stably expressed in CHO cell membrane by radioligand binding assay	ki	0.0009	uM
(1S,2R,3S,4R,5S)-2,3-dihydroxy-4-[2-iodo-6-(2-phenylethylamino)purin-9-yl]-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1266313: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyl-uronamide from human adenosine A3 receptor stably expressed in CHO cell membrane by radioligand binding assay	ki	0.0009	uM
(1S,2R,3S,4R,5S)-2,3-dihydroxy-N-methyl-4-[6-(methylamino)-2-(4-phenyltriazol-1-yl)purin-9-yl]bicyclo[3.1.0]hexane-1-carboxamide	1266313: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyl-uronamide from human adenosine A3 receptor stably expressed in CHO cell membrane by radioligand binding assay	ki	0.0010	uM
(1S,2R,3S,4R,5S)-4-[2-[4-(furan-2-yl)triazol-1-yl]-6-(methylamino)purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1266313: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyl-uronamide from human adenosine A3 receptor stably expressed in CHO cell membrane by radioligand binding assay	ki	0.0010	uM
(1S,2R,3S,4R,5S)-4-[2-[4-(3,4-difluorophenyl)triazol-1-yl]-6-(methylamino)purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1266313: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyl-uronamide from human adenosine A3 receptor stably expressed in CHO cell membrane by radioligand binding assay	ki	0.0011	uM
(1S,2R,3S,4R,5S)-4-[2-azido-6-[(3-chlorophenyl)methylamino]purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1266313: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyl-uronamide from human adenosine A3 receptor stably expressed in CHO cell membrane by radioligand binding assay	ki	0.0011	uM
(1S,2R,3S,4R,5S)-4-[2-[4-(5-chlorothiophen-2-yl)triazol-1-yl]-6-(ethylamino)purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1266313: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyl-uronamide from human adenosine A3 receptor stably expressed in CHO cell membrane by radioligand binding assay	ki	0.0012	uM
(1S,2R,3S,4R,5S)-4-[6-(ethylamino)-2-iodopurin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1266313: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyl-uronamide from human adenosine A3 receptor stably expressed in CHO cell membrane by radioligand binding assay	ki	0.0012	uM
(1S,2R,3S,4R,5S)-4-[2-[4-(1-benzofuran-2-yl)triazol-1-yl]-6-(methylamino)purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1266313: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyl-uronamide from human adenosine A3 receptor stably expressed in CHO cell membrane by radioligand binding assay	ki	0.0013	uM
(1S,2R,3S,4R,5S)-4-[6-(cyclobutylamino)-2-iodopurin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1266313: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyl-uronamide from human adenosine A3 receptor stably expressed in CHO cell membrane by radioligand binding assay	ki	0.0015	uM
(2S,3S,4R,5R)-5-[2-[2-(5-chlorothiophen-2-yl)ethynyl]-6-(methylamino)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide	1443737: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyluronamide from human A3AR expressed in HEK293T cells pre-incubated for 10 mins before radioligand addition and measured 90 mins after radioligand addition by micro beta scintillation counting analysis relative to control	ki	0.0015	uM
(1S,2R,3S,4R,5S)-4-[5-[2-(5-chlorothiophen-2-yl)ethynyl]-7-(ethylamino)imidazo[4,5-b]pyridin-3-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1443740: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyluronamide from human A3AR expressed in CHO cells	ki	0.0017	uM
(1S,2R,3S,4R,5S)-2,3-dihydroxy-N-methyl-4-[6-(methylamino)-2-(4-pyridin-2-yltriazol-1-yl)purin-9-yl]bicyclo[3.1.0]hexane-1-carboxamide	1266313: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyl-uronamide from human adenosine A3 receptor stably expressed in CHO cell membrane by radioligand binding assay	ki	0.0018	uM
(1S,2R,3S,4R,5S)-2,3-dihydroxy-N-methyl-4-[6-(methylamino)-2-(4-pyrazin-2-yltriazol-1-yl)purin-9-yl]bicyclo[3.1.0]hexane-1-carboxamide	1266313: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyl-uronamide from human adenosine A3 receptor stably expressed in CHO cell membrane by radioligand binding assay	ki	0.0022	uM
(1S,2R,3S,4R,5S)-2,3-dihydroxy-N-methyl-4-[6-(methylamino)-2-[4-(1-methylpyrazol-4-yl)triazol-1-yl]purin-9-yl]bicyclo[3.1.0]hexane-1-carboxamide	1266313: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyl-uronamide from human adenosine A3 receptor stably expressed in CHO cell membrane by radioligand binding assay	ki	0.0022	uM
(1S,2R,3S,4R,5S)-2,3-dihydroxy-N-methyl-4-[6-methyl-2-(2-phenylethynyl)purin-9-yl]bicyclo[3.1.0]hexane-1-carboxamide	1296056: Agonist activity at recombinant human adenosine A3 receptor expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP accumulation preincubated for 30 mins followed by forsolkin addition measured after 15 mins by immunoassay	ec50	0.0032	uM
(1S,2R,3S,4R,5S)-2,3-dihydroxy-N-methyl-4-[6-(methylamino)-2-(4-pyrimidin-2-yltriazol-1-yl)purin-9-yl]bicyclo[3.1.0]hexane-1-carboxamide	1266313: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyl-uronamide from human adenosine A3 receptor stably expressed in CHO cell membrane by radioligand binding assay	ki	0.0035	uM
methyl (1S,2R,3S,4R,5S)-4-[2-[2-(5-chlorothiophen-2-yl)ethynyl]-6-(methylamino)purin-9-yl]-2,3-dihydroxybicyclo[3.1.0]hexane-1-carboxylate	1443737: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyluronamide from human A3AR expressed in HEK293T cells pre-incubated for 10 mins before radioligand addition and measured 90 mins after radioligand addition by micro beta scintillation counting analysis relative to control	ki	0.0054	uM
propyl (1S,2R,3S,4R,5S)-4-[2-[2-(5-chlorothiophen-2-yl)ethynyl]-6-(methylamino)purin-9-yl]-2,3-dihydroxybicyclo[3.1.0]hexane-1-carboxylate	1443737: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyluronamide from human A3AR expressed in HEK293T cells pre-incubated for 10 mins before radioligand addition and measured 90 mins after radioligand addition by micro beta scintillation counting analysis relative to control	ki	0.0058	uM
(2S,3S,4R,5R)-5-[2-[2-(5-chlorothiophen-2-yl)ethynyl]-6-(propylamino)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide	1443737: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyluronamide from human A3AR expressed in HEK293T cells pre-incubated for 10 mins before radioligand addition and measured 90 mins after radioligand addition by micro beta scintillation counting analysis relative to control	ki	0.0063	uM
ethyl (1S,2R,3S,4R,5S)-4-[2-[2-(5-bromothiophen-2-yl)ethynyl]-6-(methylamino)purin-9-yl]-2,3-dihydroxybicyclo[3.1.0]hexane-1-carboxylate	1443737: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyluronamide from human A3AR expressed in HEK293T cells pre-incubated for 10 mins before radioligand addition and measured 90 mins after radioligand addition by micro beta scintillation counting analysis relative to control	ki	0.0064	uM
(1S,2R,3S,4R,5S)-4-[2-[4-(5-chlorothiophen-2-yl)triazol-1-yl]-6-(2-phenylethylamino)purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1266313: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyl-uronamide from human adenosine A3 receptor stably expressed in CHO cell membrane by radioligand binding assay	ki	0.0067	uM
(1S,2R,3S,4R,5S)-4-[2-[4-(5-chlorothiophen-2-yl)triazol-1-yl]-6-(cyclobutylamino)purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1266313: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyl-uronamide from human adenosine A3 receptor stably expressed in CHO cell membrane by radioligand binding assay	ki	0.0070	uM
benzyl (1S,2R,3S,4R,5S)-4-[2-[2-(5-chlorothiophen-2-yl)ethynyl]-6-(methylamino)purin-9-yl]-2,3-dihydroxybicyclo[3.1.0]hexane-1-carboxylate	1443737: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyluronamide from human A3AR expressed in HEK293T cells pre-incubated for 10 mins before radioligand addition and measured 90 mins after radioligand addition by micro beta scintillation counting analysis relative to control	ki	0.0073	uM
methyl (1S,2R,3S,4R,5S)-4-[2-[2-(5-bromothiophen-2-yl)ethynyl]-6-(methylamino)purin-9-yl]-2,3-dihydroxybicyclo[3.1.0]hexane-1-carboxylate	1443737: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyluronamide from human A3AR expressed in HEK293T cells pre-incubated for 10 mins before radioligand addition and measured 90 mins after radioligand addition by micro beta scintillation counting analysis relative to control	ki	0.0086	uM
(1S,2R,3S,4R,5S)-4-[6-[(3-chlorophenyl)methylamino]-2-[4-(5-chlorothiophen-2-yl)triazol-1-yl]purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1266313: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyl-uronamide from human adenosine A3 receptor stably expressed in CHO cell membrane by radioligand binding assay	ki	0.0090	uM
(1S,2R,3S,4R,5S)-4-[6-[2-(5-chlorothiophen-2-yl)ethynyl]-4-(methylamino)imidazo[4,5-c]pyridin-1-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1443737: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyluronamide from human A3AR expressed in HEK293T cells pre-incubated for 10 mins before radioligand addition and measured 90 mins after radioligand addition by micro beta scintillation counting analysis relative to control	ki	0.0093	uM
methyl (2S,3S,4R,5R)-5-[2-[2-(5-chlorothiophen-2-yl)ethynyl]-6-(methylamino)purin-9-yl]-3,4-dihydroxyoxolane-2-carboxylate	1443737: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyluronamide from human A3AR expressed in HEK293T cells pre-incubated for 10 mins before radioligand addition and measured 90 mins after radioligand addition by micro beta scintillation counting analysis relative to control	ki	0.0115	uM
(1S,2R,3S,4R,5S)-4-[2-[2-(5-chlorothiophen-2-yl)ethynyl]-6-methylpurin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1296056: Agonist activity at recombinant human adenosine A3 receptor expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP accumulation preincubated for 30 mins followed by forsolkin addition measured after 15 mins by immunoassay	ec50	0.0125	uM
ethyl (1S,2R,3S,4R,5S)-4-[2-[2-(5-chlorothiophen-2-yl)ethynyl]-6-(methylamino)purin-9-yl]-2,3-dihydroxybicyclo[3.1.0]hexane-1-carboxylate	1443737: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyluronamide from human A3AR expressed in HEK293T cells pre-incubated for 10 mins before radioligand addition and measured 90 mins after radioligand addition by micro beta scintillation counting analysis relative to control	ki	0.0145	uM
(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide	1324474: Displacement of [125l]N 6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyluronamide from recombinant human A3AR expressed in CHO cell membranes after 60 mins by gamma counting method	ki	0.0160	uM
butyl (1S,2R,3S,4R,5S)-4-[2-[2-(5-chlorothiophen-2-yl)ethynyl]-6-(methylamino)purin-9-yl]-2,3-dihydroxybicyclo[3.1.0]hexane-1-carboxylate	1443737: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyluronamide from human A3AR expressed in HEK293T cells pre-incubated for 10 mins before radioligand addition and measured 90 mins after radioligand addition by micro beta scintillation counting analysis relative to control	ki	0.0175	uM
propyl 6-ethyl-5-ethylsulfanylcarbonyl-2-phenyl-4-propylpyridine-3-carboxylate	1280103: Antagonist activity at adenosine A3 receptor in human NPE cells assessed as inhibition of adenosine-triggered cell shrinkage	ki	0.0190	uM
(1S,2R,3S,4R,5S)-4-[2-[2-(5-chlorothiophen-2-yl)ethynyl]-6-(dimethylamino)purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1324474: Displacement of [125l]N 6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyluronamide from recombinant human A3AR expressed in CHO cell membranes after 60 mins by gamma counting method	ki	0.0235	uM
3-methylbutyl (1S,2R,3S,4R,5S)-4-[2-[2-(5-chlorothiophen-2-yl)ethynyl]-6-(methylamino)purin-9-yl]-2,3-dihydroxybicyclo[3.1.0]hexane-1-carboxylate	1443737: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyluronamide from human A3AR expressed in HEK293T cells pre-incubated for 10 mins before radioligand addition and measured 90 mins after radioligand addition by micro beta scintillation counting analysis relative to control	ki	0.0244	uM
N-(2,6-diphenylimidazo[1,2-a]pyrazin-8-yl)-4-methoxybenzamide	1459401: Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cell membranes after 120 mins by scintillation counting method	ki	0.0250	uM
(1S,2R,3S,4R,5S)-4-[2-[2-(5-chlorothiophen-2-yl)ethynyl]purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1296056: Agonist activity at recombinant human adenosine A3 receptor expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP accumulation preincubated for 30 mins followed by forsolkin addition measured after 15 mins by immunoassay	ec50	0.0269	uM
3-O-ethyl 5-O-phenyl 2-methyl-6-phenyl-4-(2-phenylethynyl)-1,4-dihydropyridine-3,5-dicarboxylate	1280102: Displacement of [125I]AB-MECA from human brain adenosine A3 receptor expressed in HEK293 cells	ki	0.0314	uM
N-(4-cyclopropyl-1,3-thiazol-2-yl)-1-benzothiophene-2-carboxamide	1267434: Displacement of CA200645 from human adenosine A3 receptor expressed in CHO CRE-SPAP cells incubated for 1 hr by fluorescence analysis	ki	0.0339	uM
(1S,2R,3S,4R,5S)-4-[2-chloro-6-(dicyclopropylmethylamino)purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide	1324474: Displacement of [125l]N 6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyluronamide from recombinant human A3AR expressed in CHO cell membranes after 60 mins by gamma counting method	ki	0.0340	uM
N-(2,6-diphenylimidazo[1,2-a]pyrazin-8-yl)-4-fluorobenzamide	1459401: Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cell membranes after 120 mins by scintillation counting method	ki	0.0380	uM
(2R,3R,4S,5S)-3,4-dihydroxy-2-[6-[(3-iodophenyl)methylamino]purin-9-yl]-1-oxa-7-azaspiro[4.4]nonan-6-one	1280103: Antagonist activity at adenosine A3 receptor in human NPE cells assessed as inhibition of adenosine-triggered cell shrinkage	ic50	0.0420	uM
propan-2-yl (1S,2R,3S,4R,5S)-4-[2-[2-(5-chlorothiophen-2-yl)ethynyl]-6-(methylamino)purin-9-yl]-2,3-dihydroxybicyclo[3.1.0]hexane-1-carboxylate	1443737: Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5’-N-methyluronamide from human A3AR expressed in HEK293T cells pre-incubated for 10 mins before radioligand addition and measured 90 mins after radioligand addition by micro beta scintillation counting analysis relative to control	ki	0.0429	uM
N-(2-phenylimidazo[1,2-a]pyrazin-8-yl)benzamide	1459401: Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cell membranes after 120 mins by scintillation counting method	ki	0.0520	uM

CTD chemical–gene interactions

1 total (human), top 1 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Leflunomide	increases expression	1

ChEMBL screening assays

27 unique, capped per target: 27 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3744100	Binding	Binding affinity to adenosine A3 receptor (unknown origin)	New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists — Medchemcomm

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00211796	PHASE4	COMPLETED	Divalproex Sodium ER in Adult Autism
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00409747	PHASE4	COMPLETED	Minocycline to Treat Childhood Regressive Autism
NCT00576732	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00844753	PHASE4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01098383	PHASE4	UNKNOWN	Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02069977	PHASE4	UNKNOWN	Study to Evaluate the Efficacy and Safety of Aripiprazole
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02199925	PHASE4	UNKNOWN	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02255565	PHASE4	COMPLETED	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT00036231	PHASE3	TERMINATED	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
NCT00036244	PHASE3	COMPLETED	Synthetic Human Secretin in Children With Autism
NCT00065884	PHASE3	UNKNOWN	Valproate Response in Aggressive Autistic Adolescents
NCT00065962	PHASE3	COMPLETED	Secretin for the Treatment of Autism
NCT00252603	PHASE3	COMPLETED	Galantamine Versus Placebo in Childhood Autism
NCT00346736	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00352248	PHASE3	COMPLETED	Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder
NCT00352352	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00355329	PHASE3	COMPLETED	Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation
NCT00498173	PHASE3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00541346	PHASE3	COMPLETED	A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms